 Connection
Michael Bristow to Clinical Trials as Topic
This is a "connection" page, showing publications Michael Bristow has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.102 |
|
|
|
-
Bristow MR, Sharma K, Assmann SF, Linas S, Gersh BJ, Grady C, Rice MM, Singh S, Boineau R, McKinlay SM, Greenberg BH. Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. Eur J Heart Fail. 2017 04; 19(4):457-465.
Score: 0.397
-
Fiuzat M, Bristow MR. Pharmacogenetics in heart failure trials. Heart Fail Clin. 2011 Oct; 7(4):553-9.
Score: 0.278
-
Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 08; 11(8):e002210.
Score: 0.112
-
Rivera DA, Bristow MR. Cardiac resynchronization--a heart failure perspective. Ann Noninvasive Electrocardiol. 2005 Oct; 10(4 Suppl):16-23.
Score: 0.046
-
Linseman JV, Bristow MR. Drug therapy and heart failure prevention. Circulation. 2003 Mar 11; 107(9):1234-6.
Score: 0.038
-
Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003 Mar 04; 107(8):1100-2.
Score: 0.038
-
Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001 May; 33(5):887-905.
Score: 0.034
-
Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail. 2000 Jun; 6(2 Suppl 1):8-14.
Score: 0.032
-
O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. Improving Heart Failure Therapeutics Development in the United States: The?Heart?Failure?Collaboratory. J Am Coll Cardiol. 2018 01 30; 71(4):443-453.
Score: 0.027
-
Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997 Mar 15; 79(6):794-8.
Score: 0.025
-
Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol. 2015 Apr 21; 65(15):1567-82.
Score: 0.022
-
Hinterberg MA, Kao DP, Bristow MR, Hunter LE, Port JD, G?rg C. Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pac Symp Biocomput. 2015; 419-30.
Score: 0.022
-
Bristow MR. Use of oral enoximone in pharmacologic bridging to cardiac transplantation. Z Kardiol. 1994; 83 Suppl 2:15-9.
Score: 0.020
-
Cohn JN, Bristow MR, Chien KR, Colucci WS, Frazier OH, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Reinlib L. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation. 1997 Feb 18; 95(4):766-70.
Score: 0.006
-
Gilbert EM, Bristow MR, Mason JW. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study. Am J Cardiol. 1987 Aug 14; 60(5):57C-62C.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|